b7-h3 car-t
Cell therapyexperimental
Clinical trial activity
13 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2020 (NCT04077866)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adrenal Cortex Neoplasms · Phase 1
- Brain Diseases · Phase 1
- Carcinoma · Phase 1
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Central Nervous System Neoplasms · Phase 1
- Desmoplastic Small Round Cell Tumor · Phase 1
- Ependymoma · Phase 1
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Hepatoblastoma · Phase 1
- Medulloblastoma · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Neuroblastoma · Phase 1
- Neurofibrosarcoma · Phase 1
- Osteosarcoma · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Rhabdoid Tumor · Phase 1
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 1
- Sarcoma, Clear Cell · Phase 1
- Sarcoma, Ewing · Phase 1
- Wilms Tumor · Phase 1
Mechanism of action
- CD276 antigenImmunity, passive
CD276 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07222735 | Phase 1 | Dec 5, 2025 | St. Jude Children's Hospital |
| NCT06825455 | Early Phase 1 (Phase 1) | Mar 1, 2025 | Peking University |
| NCT06646627 | Phase 1 | Nov 30, 2024 | Stanford University |
| NCT06500819 | Phase 1 | Jul 11, 2024 | Stanford University |
| NCT06018363 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2023 | Soochow University |
| NCT05835687 | Phase 1 | Apr 27, 2023 | St. Jude Children's Hospital |
| NCT05474378 | Phase 1 | Jul 12, 2022 | Stanford University |
| NCT04897321 | Phase 1 | Apr 30, 2022 | St. Jude Children's Hospital |
| NCT05323201 | Phase 1/Phase 2 (Phase 2) | Feb 10, 2022 | Xuzhou Medical University |
| NCT05241392 | Phase 1 | Jan 27, 2022 | Capital Medical University |
| NCT05211557 | Phase 1/Phase 2 (Phase 2) | Nov 16, 2021 | Xuzhou Medical University |
| NCT04385173 | Phase 1 | Jun 1, 2020 | BoYuan RunSheng Pharma (Hangzhou) Co., Ltd., Zhejiang University |
| NCT04077866 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2020 | BoYuan RunSheng Pharma (Hangzhou) Co., Ltd., Huzhou University, Ningbo Yinzhou People's Hospital, Zhejiang University |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Stanford University | Academic/Hospital | 3 | 3 | 1 | 2022 |
| St. Jude Children's Hospital | Academic/Hospital | 3 | 3 | 1 | 2022 |
| BoYuan RunSheng Pharma (Hangzhou) Co., Ltd. | For profit | 2 | 0 | 2 | 2020 |
| Xuzhou Medical University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Huzhou University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Ningbo Yinzhou People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2023 |
10 organizations
Page 1 / 1